| David M Dembski, MD | |
|
3237 Maple Ave, Zanesville, OH 43701-1312 | |
| (740) 450-3400 | |
| (740) 450-3420 |
| Full Name | David M Dembski |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 34 Years |
| Location | 3237 Maple Ave, Zanesville, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972586139 | NPI | - | NPPES |
| 2745346 | Medicaid | OH | |
| 4759480 | Medicaid | MI | |
| 381358036011 | Other | MI | TRICARE |
| P00288286 | Other | MI | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 060916 (Michigan) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | 3589360D (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kidney Care Of Centers Of Cambridge | Cambridge, OH | Dialysis facility |
| Kidney Care Centers Of Coshocton, Ohio | Coshocton, OH | Dialysis facility |
| Kidney Care Centers Of Zanesville | Zanesville, OH | Dialysis facility |
| Davita Zanesville Dialysis | Zanesville, OH | Dialysis facility |
| Genesis Hospital | Zanesville, OH | Hospital |
| Southeastern Ohio Regional Medical Center | Cambridge, OH | Hospital |
| Barnesville Hospital Association, Inc | Barnesville, OH | Hospital |
| Coshocton Regional Medical Center | Coshocton, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nephrology Consultants Of Southeastern Ohio, Inc. | 7012912157 | 5 |
News Archive
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
Beckman Coulter , a global leader in clinical diagnostics, announced today that South West London Pathology (SWLP) has implemented DxH 900 hematology analyzers and the Early Sepsis Indicator across the SWLP network.
MultiCell Technologies, Inc. is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network's Toronto General Hospital expanding the scope of the research project to evaluate MCT-485 in animal models for the treatment of primary liver cancer.
In the study, published in a recent issue of the journal Neurosurgery, 50 percent of stroke patients had little or no neurological disability one to three months after clot-dissolving medication was delivered directly to the site of the blockages, compared to 39 percent of patients with similarly good outcomes documented in a large national trial of intravenous (IV) drug treatment for stroke.
Choosing the right medications is essential to gaining control over symptoms as allergy season comes into full bloom, allergy specialists at UT Southwestern Medical Center warn.
› Verified 3 days ago
| Entity Name | Nephrology Consultants Of Southeastern Ohio, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730284563 PECOS PAC ID: 7012912157 Enrollment ID: O20060925000416 |
News Archive
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
Beckman Coulter , a global leader in clinical diagnostics, announced today that South West London Pathology (SWLP) has implemented DxH 900 hematology analyzers and the Early Sepsis Indicator across the SWLP network.
MultiCell Technologies, Inc. is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network's Toronto General Hospital expanding the scope of the research project to evaluate MCT-485 in animal models for the treatment of primary liver cancer.
In the study, published in a recent issue of the journal Neurosurgery, 50 percent of stroke patients had little or no neurological disability one to three months after clot-dissolving medication was delivered directly to the site of the blockages, compared to 39 percent of patients with similarly good outcomes documented in a large national trial of intravenous (IV) drug treatment for stroke.
Choosing the right medications is essential to gaining control over symptoms as allergy season comes into full bloom, allergy specialists at UT Southwestern Medical Center warn.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David M Dembski, MD 3237 Maple Ave, Zanesville, OH 43701-1312 Ph: (740) 450-3400 | David M Dembski, MD 3237 Maple Ave, Zanesville, OH 43701-1312 Ph: (740) 450-3400 |
News Archive
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
Beckman Coulter , a global leader in clinical diagnostics, announced today that South West London Pathology (SWLP) has implemented DxH 900 hematology analyzers and the Early Sepsis Indicator across the SWLP network.
MultiCell Technologies, Inc. is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network's Toronto General Hospital expanding the scope of the research project to evaluate MCT-485 in animal models for the treatment of primary liver cancer.
In the study, published in a recent issue of the journal Neurosurgery, 50 percent of stroke patients had little or no neurological disability one to three months after clot-dissolving medication was delivered directly to the site of the blockages, compared to 39 percent of patients with similarly good outcomes documented in a large national trial of intravenous (IV) drug treatment for stroke.
Choosing the right medications is essential to gaining control over symptoms as allergy season comes into full bloom, allergy specialists at UT Southwestern Medical Center warn.
› Verified 3 days ago
Dany S. Abou Abdallah, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2951 Maple Ave, Zanesville, OH 43701 Phone: 740-454-5000 | |
Randy L Mills, DO Nephrology Medicare: Accepting Medicare Assignments Practice Location: 800 Forest Ave, Zanesville, OH 43701 Phone: 330-493-4443 | |
Dr. Daniel Scheerer, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1210 Ashland Ave, Zanesville, OH 43701 Phone: 740-454-8551 Fax: 740-454-2411 | |
Farid Bounif, MD Nephrology Medicare: Medicare Enrolled Practice Location: 800 Forest Ave, Zanesville, OH 43701 Phone: 330-493-4443 Fax: 330-493-8677 | |
Dr. Brian William Luft, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 751 Forest Ave Ste 202, Zanesville, OH 43701 Phone: 740-450-1687 Fax: 740-450-1693 | |
Jignesh Jashawant Modi, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 945 Bethesda Dr Ste 110, Zanesville, OH 43701 Phone: 740-450-6147 | |
Duane P Pool, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 751 Forest Ave, Ste 301, Zanesville, OH 43701 Phone: 740-454-0804 Fax: 740-450-3447 |